Login to Your Account



Financings Roundup


Thursday, March 3, 2011
BerGenBio A/S, of Bergen, Norway, secured NOK7 million (US$1.3 million) from local Sarsia Seed and Development Funds to continue its R&D activities in cancer. The firm is working on its CellSelect platform, which uses information from RNAi screening studies to identify drug targets

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription